Perforomist (formoterol) is a brand-name drug that’s prescribed for chronic obstructive pulmonary disease (COPD) in adults. Perforomist comes as a liquid that’s inhaled with a nebulizer twice per day.

San Diego, Calif., May 19, 2009 – Data from two presentations highlighting the use of Perforomist® (formoterol fumarate) Inhalation Solution in moderate to severe chronic obstructive pulmonary disease ...

Napa, CA (May 21, 2007) -- Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist™ (formoterol fumarate) Inhalation Solution, delivered by ...

Perforomist is a solution formulation of the long-acting beta 2-agonist formoterol fumarate, which is administered by inhalation via nebulization. It acts as a bronchodilator by stimulating beta 2 ...

PISCATAWAY, N.J., Dec. 1, 2022 /PRNewswire/ -- Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals"), announced today the U.S. approval of a generic version of Perforomist® [1] (formoterol fumarate) ...

PITTSBURGH, July 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the United States District Court for the Northern District of West Virginia has granted Mylan's motion for ...

Mylan Inc. (NASDAQ: MYL) recently prevailed in the United States District Court for the Northern District of West Virginia in a patent dispute involving Perforomist® (formoterol fumarate) Inhalation ...

PITTSBURGH — Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol ...

PITTSBURGH, March 24, 2014 /PRNewswire/ -- Mylan Inc. today announced the United States District Court for the Northern District of West Virginia issued a decision upholding the validity of all ...